Prospective Study of Topical Testosterone Gel (AndroGel) Versus Intramuscular Testosterone in Testosterone-Deficient HIV-Infected Men

REFERENCES

• Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhyth-micity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278–1281.
   Google Scholar
• Gray A, Feldman HA, McKinley JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 199173: 1016–1025.
   Google Scholar
• Tenover JL. Male hormone replacement therapy including "andropause." Endocrinol Metab Clin North Am. 1998; 27:969–987.
   PubMed Web of Science ®Google Scholar
• Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46: 410–413.
   PubMed Web of Science ®Google Scholar
• Croxson TS, Chapman WE, Miller LK, et al. Changes in the hypothalamic-pituitary-gonadal axis in human immunode-ficiency virus-infected homosexual men. J Clin Endocrinol Metab. 1989;68:317–321.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodefi-ciency syndrome and wasting. J Clin Endocrinol Metab. 1996;81:4051–4058.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Dempsey MA, Ladenson PW, Polk BE Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84(3 Pt 2):611–616.
   PubMed Web of Science ®Google Scholar
• Goodley GO, Loveless MO, Nelson HD, Goodley MK. En-docrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr 1994;7:46–51.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Medi-cal guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002;8:440–456.
   PubMedGoogle Scholar
• Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000; 283:763–770.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Askari H, et al. Effects of an-drogen administration in men with the AIDS wasting syn-drome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18–26.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testos-terone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83: 3155–3162.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychooharmacol. 1999; 19:19–27.
   Google Scholar
• Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocri-nol Metab. 2000;85:2839–2853.
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term tes-tosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin En-docrinol Metab. 2004;89:2085–2098.
   PubMed Web of Science ®Google Scholar
• Cofrancesco J Jr, Whalen JJ 3rd, Dobs AS. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16: 254–265.
   Google Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, ef-ficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly in-jections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999; 84:3469–3478.
   PubMed Web of Science ®Google Scholar
• Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. 1994;23:857–875.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Lawrence DA. Treatment of male hypogonad-ism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51:1335–1339.
   PubMed Web of Science ®Google Scholar
• Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982; 37:425–430.
   PubMed Web of Science ®Google Scholar
• Wang C, Berman N, Longstreth JA, et al. Pharmacokinet-ics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85:964–969.
   PubMed Web of Science ®Google Scholar
• Depe-Testosterone (testosterone cypionate) Full Prescrib-ing Information. Kalamazoo, MI: Pharmacia & Upjohn; 2002.
   Google Scholar
• AndroGel® (testosterone gel) Full Prescribing Information. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2005.
   Google Scholar
• Nankin HR. Hormone kinetics after intramuscular testos-terone cypionate. Fertil SteriL 1987;47:1004–1009.
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85: 4500–4510.
   PubMed Web of Science ®Google Scholar
• Technical Insert. DPC's Coat-a-Count® Free Testosterone assay. March 18, 2005.
   Google Scholar
• Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. De-velopment and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHl) quality of life instrument. Qual Life Res. 1996;5:450–463.
   Google Scholar
• Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHl) quality of life in-strument. Qual Life Res. 1997;6:572–584.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, Rabkin R. A double-blind, pla-cebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57: 141–147.
   PubMed Web of Science ®Google Scholar
• Badia X. The measurement of health-related quality of life in prospective drug therapy studies in HIV-infected pa-tients. AIDS Rev. 1999;1:213–220.
   Google Scholar
• Collazos J, Martinez E, Mayo J, Lbarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral ther-apy. AIDS. 2002;16:934–937.
   PubMed Web of Science ®Google Scholar
• Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T. HIV protease inhibitors saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testoster-one and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Let. 1997;93: 215–219.
   PubMed Web of Science ®Google Scholar
• WHO (World Health Organization). Human immunodefi-ciency virus and acquired immunodeficiency syndrome (Chapter XII). In: Adherence to Long-Term Therapies: Evi-dence for Action. Geneva, Switzerland: World Health Orga-nization; 2003.
   Google Scholar
• Clay PG. Program savings associated with switching tes-tosterone intramuscular injections to topical gel in HIV infected males. Curr Med Res Op/n. 2004;20:461–468.
   PubMed Web of Science ®Google Scholar